ACTH-secreting metastatic prostate cancer with neuroendocrine differentiation

  1. Bashar Hassan 1,
  2. Yara Yazbeck 2,
  3. Vanessa Akiki 2,
  4. Ibrahim Salti 2 and
  5. Arafat Tfayli 3
  1. 1 Faculty of Medicine, American University of Beirut, Beirut, Lebanon
  2. 2 Division of Endocrinology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon
  3. 3 Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon
  1. Correspondence to Professor Arafat Tfayli; at35@aub.edu.lb

Publication history

Accepted:09 Dec 2022
First published:19 Dec 2022
Online issue publication:19 Dec 2022

Case reports

Case reports are not necessarily evidence-based in the same way that the other content on BMJ Best Practice is. They should not be relied on to guide clinical practice. Please check the date of publication.

Abstract

Cushing’s syndrome (CS) due to ectopic adrenocorticotropic hormone (ACTH) secretion (EAS) can result from a variety of tumours and rarely from those of prostatic origin. We present a male patient in his early 60s with ACTH-secreting metastatic prostate adenocarcinoma with neuroendocrine differentiation (ICD-O code 8574/3) years after prostatectomy and androgen-deprivation therapy, initially presenting with Cushingoid features. After open radical prostatectomy and bilateral orchiectomy for disease recurrence, the patient was found to have metastatic liver and bone lesions highly suggestive of metastatic prostatic cancer. About 10% of cells on liver biopsy expressed ACTH, a finding consistent with EAS as the cause of CS. His stay was complicated with multiple infections and ultimate death. Hence, we report a case of metastatic prostate adenocarcinoma with neuroendocrine differentiation who presented with CS. We also emphasize the importance of adequate and timely treatment.

Background

Cushing’s syndrome (CS) can result from a paraneoplastic syndrome due to ectopic adrenocorticotropic secretion, which accounts for 10%–20% of cases of excess adrenocorticotropic hormone (ACTH).1 Because of the severity and rapid progression, patients with ectopic ACTH secretion (EAS) rarely have the typical Cushingoid phenotype.2 3 In fact, they typically present with severe hypertension, hyperglycemia, hypokalemic metabolic alkalosis, and increased susceptibility to infections, bruises and bone fractures.1 The non-pituitary tumours, which are most commonly associated with ectopic ACTH production, are bronchial carcinoid tumours, small cell lung cancers, medullary thyroid cancers, pheochromocytomas and rarely prostate cancers, among others.4

Prostate cancer is the second most common cancer and the third leading cause of cancer-related death in men worldwide.5 Although rare, prostate cancer can differentiate into neuroendocrine, small cell and adenocarcinomas with ectopic ACTH secretion.6–15 Neuroendocrine differentiation has been documented to be induced by radiotherapy, chemotherapy and androgen-deprivation therapy and has been associated with prostate cancer progression and poor prognosis.16

Case presentation

A male patient, in his early 60s, presented to us 2 years ago. Ten years prior to his presentation, he was treated for prostatic adenocarcinoma with radical prostatectomy. Five years prior to his presentation, he had disease recurrence with bone metastasis. Consequently, the patient underwent bilateral orchiectomy and took 6 cycles of docetaxel with poor response and disease progression. As a result, the patient was started on Enzalutamide 3 years prior to his presentation. The patient also had osteoporosis (treated with denosumab), hypertension, obstructive sleep apnea and chronic hypocalcemia of unclear aetiology, likely due to denosumab administration.

On presentation to our institution, the patient had abdominal distention, facial and bilateral upper and lower limb edema. Physical examination was notable for ascites and severe hypertension of 192/100 mm Hg, as well as the previously mentioned increased abdominal girth, facial puffiness and bilateral pitting edema of the four limbs.

Investigations and differential diagnosis

Laboratory test results on presentation are shown in table 1.

Table 1

Laboratory results of the patient on presentation

Table 1

Laboratory results of the patient on presentation

Management included cessation of enzalutamide, increase in amlodipine dosage to 10 mg (daily) for blood pressure control and initiation of 600 mg of calcium carbonate (Caltrate) and 0.5 mcg of alfacalcidol (One-alpha) (two times per day, each) for hypocalcemia. Abdominal CT scan showed innumerable hypo-enhancing lesions involving all liver segments with peripheral rim enhancement consistent with metastatic lesions (figure 1), as well as a right adrenal nodule. CT scan of the chest done later was negative for any primary malignant features in the lungs and thorax, further confirming the prostatic origin of the metastasis.

Figure 1

Abdominal CT illustrating liver hypo-enhancing lesions with peripheral rim enhancement indicating metastasis.

Liver biopsy and proper immunostaining were done a week after initial presentation. Synaptophysin, thyroid transcription factor-1 (TTF-1) and alpha-methylacyl-CoA racemase (AMACR/P504S) stains were positive, while prostate-specific antigen (PSA) was negative (figure 2A,B). ACTH stain was not done yet. The biopsy findings thus represented high-grade prostate adenocarcinoma with neuroendocrine differentiation (ICD-O code 8574/3), especially when put in the proper context of metastatic prostate cancer to bones. Accordingly, he was scheduled to receive cisplatin-etoposide a week later.

Figure 2

Liver biopsies (A–C) showing positive staining for synaptophysin, thyroid transcription factor-1 and ectopic adrenocorticotropic hormone, respectively.

One day before his scheduled first chemotherapy session, the patient was readmitted for low calcium levels. His hypocalcemia was managed with intravenous calcium, 600 mcg of oral calcium tablets (three times daily) and 0.5 mcg of One-alpha tablets (two times per day). The patient remained hyperglycemic (273 mg/dL) and thrombocytopenic (platelets 75 000; reference range (ref) 1 50 000–400 000), most likely from bone marrow involvement. He also had mildly elevated total bilirubin (1.3 mg/dL; ref 0.0–1.2 mg/dL) and direct bilirubin (0.7 mg/dL; ref 0.0–0.3 mg/dL). Due to elevated bilirubin levels, abdominal ultrasound was done showing no evidence of gallbladder disease, but innumerable liver lesions. He was started on cisplatin-etoposide for his metastatic lesions the day after.

Workup of the right adrenal nodule is shown in table 2.

Table 2

Workup of the secretory adrenal nodule including that of hypercortisolism

Test Day A Day B Day C Day D
Letters are used to refer to days, instead of dates/numbers, for the sake of patient deidentification. Days A, B, C and D are each separated by 1 day.
Cortisol level 98.00 µg/dL 105.00 µg/dL 106.80 µg/dL 106.00 µg/dL
Dexamethasone suppression tests 1 mg at 23:00 2 mg at 23:00 2 mg every 6 hours for 48 hours –
ACTH 1334 pg/mL
(ref 11–60)
Cortisol, 24-hour Ur 4362 µg/24 hours
(ref 11–73)
DHEA-S 2864 ng/mL
(ref 517–2950)
Aldosterone, 24-hour Ur 2.69 µg/24 hours.
(ref 1.19–28.1 µg/24 hours)
Serum metanephrines <0.10 nmol/L
(ref <0.37)

Treatment

For the treatment of the patient’s hypercortisolism, mitotane, ketoconazole or mifepristone was recommended. A delay in the start of the medication was experienced due to unavailability in the country at that time. When made available, oral mitotane 500 mg (three times per day) was started. Table 3 shows electrolyte changes before and after mitotane initiation.

Table 3

Sodium and potassium levels before and after mitotane initiation

Reference range Day X
(9 days before mitotane initiation)		 Day Y
(11 days after mitotane initiation)
Letters are used to refer to days, instead of dates/numbers, for the sake of patient deidentification. Days D and X are separated by 5 days.
Sodium 135–145 mmol/L 148 140
Potassium 3.5–5.1 mmol/L 3.3 4.0

Outcome and follow-up

The patient had a deteriorating mental status, and a nasogastric tube was inserted. Mitotane could not be crushed. Because he was a poor surgical candidate, bilateral adrenalectomy could not be done. The patient then had multiple infections and eventually passed away.

Discussion

The patient we report in this paper is a case of CS due to ectopic ACTH secretion from metastatic prostatic adenocarcinoma with neuroendocrine differentiation (ICD-O code 8574/3).

It was concluded that our patient’s metastatic hepatic tumour was prostatic in origin, mainly based on biopsy findings including AMACR/P504S and TTF-1 positivity. The AMACR/P504S is a marker used for the immunodetection of prostate adenocarcinoma, with 97% sensitivity and 92% specificity.17 Additionally, TTF-1 was reported to be expressed in metastatic prostate adenocarcinoma after excluding primary lung or thorax malignancy, which we also did using CT scans.18 Furthermore, the primary prostatic origin of the hepatic lesions was inferred from the positive personal history of prostatic adenocarcinoma metastatic to the bones. Immunohistochemistry showing positivity for synaptophysin also favoured a diagnosis of metastatic adenocarcinoma of the prostate with neuroendocrine differentiation (ICD-O code 8574/3).19 The likelihood of this diagnosis was also due to the metastasis and neuroendocrine differentiation of our patient’s tumour after docetaxel12 15 16 and enzalutamide therapy.

Studies have shown variable response to docetaxel in the treatment of prostate cancer, including many patients who do not respond to treatment.20 There is current evidence showing the effect of docetaxel in reducing tumour metastasis, on one hand, and increasing its resistance to treatment, contributing to metastasis, on the other hand.20 Although docetaxel has been shown to trigger neuroendocrine differentiation of prostate cancer, and thus treatment resistance and disease progression, it has also been shown to have a synergistic effect with octreotide in the treatment of castration-resistant prostate cancer with neuroendocrine differentiation and somatostatin receptor scintigraphy.16 21 These variable outcomes of docetaxel treatment can be clinically predicted by chromogranin A (CgA) response.21 Favourable response to docetaxel treatment in castration-resistant prostate cancer is associated with decreasing CgA, while rising CgA may be associated with poor prognosis.21 Nonetheless, CgA was not measured in our patient.

The management of CS due to ectopic ACTH secretion from a neuroendocrine tumour is complex and should focus on two levels: CS and neuroendocrine tumour treatment.22 Ectopic ACTH syndrome is often considered an endocrine emergency due to the excessive hypercortisolism and its consequences.22 Although the most optimal treatment of ACTH-secreting tumours is complete tumour resection, few available options remain when the tumour is metastatic, as is the case in our patient post-radical prostatectomy.22 Aside from symptomatic management, available treatment options include androgen-deprivation therapy or adrenalectomy, when medical treatment fails.22 However, the former has been linked to treatment resistance, disease progression, and poor prognosis, which also might have been the case in our patient.16 This signifies the need for new treatment modalities in the setting of metastatic neuroendocrine tumours, in general, and ACTH-secreting neuroendocrine tumours metastatic from the prostate, in particular. So far, ketoconazole remains the most used agent for the treatment of CS due to EAS, as it both suppresses the response to high cortisol and has antiandrogenic effect.

Learning points

  • Cushing’s syndrome (CS) is possible due to metastatic prostate cancer with neuroendocrine differentiation, even years after prostatectomy.

  • Ectopic adrenocorticotropic hormone (ACTH) secretion (EAS) should be kept on the differential as an etiology for CS in a patient presenting with Cushingoid features with history of prostate cancer.

  • The timely workup for metastasis and EAS in such patients is important.

  • New treatment regimens are needed to better manage metastatic prostate cancer, with less induction of neuroendocrine differentiation, currently a well-recognized mechanism of treatment resistance and disease progression.

Ethics statements

Patient consent for publication

Footnotes

  • Contributors BH drafted the paper. BH, YY, and VA designed the figures and tables. All authors contributed to patient care and editing the final manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Case reports provide a valuable learning resource for the scientific community and can indicate areas of interest for future research. They should not be used in isolation to guide treatment choices or public health policy.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

References

  1. ↵
    1. Ilias I ,
    2. Torpy DJ ,
    3. Pacak K , et al
    . Cushing's syndrome due to ectopic corticotropin secretion: twenty years' experience at the National Institutes of health. J Clin Endocrinol Metab 2005;90:4955–62.doi:10.1210/jc.2004-2527 pmid:http://www.ncbi.nlm.nih.gov/pubmed/15914534
  2. ↵
    1. Bolton DM ,
    2. Chiu ST ,
    3. Clarke S , et al
    . Primary small cell carcinoma of the prostate: unusual modes of presentation. Aust N Z J Surg 1994;64:91–4.doi:10.1111/j.1445-2197.1994.tb02150.x pmid:http://www.ncbi.nlm.nih.gov/pubmed/7507315
  3. ↵
    1. Têtu B ,
    2. Ro JY ,
    3. Ayala AG , et al
    . Small cell carcinoma of the prostate. Part I. A clinicopathologic study of 20 cases. Cancer 1987;59:1803–9.doi:10.1002/1097-0142(19870515)59:10<1803::AID-CNCR2820591019>3.0.CO;2-X pmid:http://www.ncbi.nlm.nih.gov/pubmed/3030528
  4. ↵
    1. Isidori AM ,
    2. Kaltsas GA ,
    3. Pozza C , et al
    . The ectopic adrenocorticotropin syndrome: clinical features, diagnosis, management, and long-term follow-up. J Clin Endocrinol Metab 2006;91:371–7.doi:10.1210/jc.2005-1542 pmid:http://www.ncbi.nlm.nih.gov/pubmed/16303835
  5. ↵
    1. Rosario E ,
    2. Rosario DJ
    . Localized Prostate Cancer. In: StatPearls. Treasure Island (FL): StatPearls Publishing, 20202020.
  6. ↵
    1. Ghali VS ,
    2. Garcia RL
    . Prostatic adenocarcinoma with carcinoidal features producing adrenocorticotropic syndrome. immunohistochemical study and review of the literature. Cancer 1984;54:1043–8.doi:10.1002/1097-0142(19840915)54:6<1043::AID-CNCR2820540619>3.0.CO;2-U pmid:http://www.ncbi.nlm.nih.gov/pubmed/6147188
  7. ↵
    1. Rickman T ,
    2. Garmany R ,
    3. Doherty T , et al
    . Hypokalemia, metabolic alkalosis, and hypertension: Cushing's syndrome in a patient with metastatic prostate adenocarcinoma. Am J Kidney Dis 2001;37:838–46.doi:10.1016/S0272-6386(01)80134-7 pmid:http://www.ncbi.nlm.nih.gov/pubmed/11273885
  8. ↵
    1. Alwani RA ,
    2. Neggers SJCMM ,
    3. van der Klift M , et al
    . Cushing's syndrome due to ectopic ACTH production by (neuroendocrine) prostate carcinoma. Pituitary 2009;12:280–3.doi:10.1007/s11102-008-0100-z pmid:http://www.ncbi.nlm.nih.gov/pubmed/18322802
  9. ↵
    1. Alshaikh OM ,
    2. Al-Mahfouz AA ,
    3. Al-Hindi H , et al
    . Unusual cause of ectopic secretion of adrenocorticotropic hormone: Cushing syndrome attributable to small cell prostate cancer. Endocr Pract 2010;16:249–54.doi:10.4158/EP09243.CR pmid:http://www.ncbi.nlm.nih.gov/pubmed/20061271
  10. ↵
    1. Nadal R ,
    2. Schweizer M ,
    3. Kryvenko ON , et al
    . Small cell carcinoma of the prostate. Nat Rev Urol 2014;11:213–9.doi:10.1038/nrurol.2014.21 pmid:http://www.ncbi.nlm.nih.gov/pubmed/24535589
  11. ↵
    1. Shrosbree J ,
    2. Pokorny A ,
    3. Stone E , et al
    . Ectopic Cushing syndrome due to neuroendocrine prostatic cancer. Intern Med J 2016;46:630–2.doi:10.1111/imj.13063 pmid:http://www.ncbi.nlm.nih.gov/pubmed/27170243
  12. ↵
    1. Ramalingam S ,
    2. Eisenberg A ,
    3. Foo WC , et al
    . Treatment-Related neuroendocrine prostate cancer resulting in Cushing's syndrome. Int J Urol 2016;23:1038–41.doi:10.1111/iju.13225 pmid:http://www.ncbi.nlm.nih.gov/pubmed/27766686
  13. ↵
    1. Elston MS ,
    2. Crawford VB ,
    3. Swarbrick M , et al
    . Severe Cushing's syndrome due to small cell prostate carcinoma: a case and review of literature. Endocr Connect 2017;6:R80–6.doi:10.1530/EC-17-0081 pmid:http://www.ncbi.nlm.nih.gov/pubmed/28584167
  14. ↵
    1. Murphy N ,
    2. Shen J ,
    3. Shih A , et al
    . Paraneoplastic syndrome secondary to treatment emergent neuroendocrine tumor in metastatic castration-resistant prostate cancer: a unique case. Clin Genitourin Cancer 2019;17:e56–60.doi:10.1016/j.clgc.2018.09.002 pmid:http://www.ncbi.nlm.nih.gov/pubmed/30279116
  15. ↵
    1. Soundarrajan M ,
    2. Zelada H ,
    3. Fischer JV , et al
    . Ectopic adrenocorticotropic hormone syndrome due to metastatic prostate cancer with neuroendocrine differentiation. AACE Clin Case Rep 2019;5:e192–6.doi:10.4158/ACCR-2018-0429 pmid:http://www.ncbi.nlm.nih.gov/pubmed/31967032
  16. ↵
    1. Hu C-D ,
    2. Choo R ,
    3. Huang J
    . Neuroendocrine differentiation in prostate cancer: a mechanism of radioresistance and treatment failure. Front Oncol 2015;5:90.doi:10.3389/fonc.2015.00090 pmid:http://www.ncbi.nlm.nih.gov/pubmed/25927031
  17. ↵
    1. Jiang Z ,
    2. Wu CL ,
    3. Woda BA , et al
    . Alpha-Methylacyl-Coa racemase: a multi-institutional study of a new prostate cancer marker. Histopathology 2004;45:218–25.doi:10.1111/j.1365-2559.2004.01930.x pmid:http://www.ncbi.nlm.nih.gov/pubmed/15330799
  18. ↵
    1. Lim TK-H ,
    2. Teo C ,
    3. Giron DM , et al
    . Thyroid transcription factor-1 may be expressed in ductal adenocarcinoma of the prostate:a potential pitfall. J Clin Pathol 2007;60:941–3.doi:10.1136/jcp.2007.047829 pmid:http://www.ncbi.nlm.nih.gov/pubmed/17660340
  19. ↵
    1. Humphrey PA ,
    2. Moch H ,
    3. Cubilla AL , et al
    . The 2016 who classification of tumours of the urinary system and male genital Organs-Part B: prostate and bladder tumours. Eur Urol 2016;70:106–19.doi:10.1016/j.eururo.2016.02.028 pmid:http://www.ncbi.nlm.nih.gov/pubmed/26996659
  20. ↵
    1. Sarkar D ,
    2. Singh SK ,
    3. Mandal AK , et al
    . Plasma chromogranin A: clinical implications in patients with castrate resistant prostate cancer receiving docetaxel chemotherapy. Cancer Biomark;8:81–7.doi:10.3233/CBM-2011-0198 pmid:http://www.ncbi.nlm.nih.gov/pubmed/21896995
  21. ↵
    1. Priftakis D ,
    2. Kritikos N ,
    3. Stavrinides S , et al
    . Neuroendocrine differentiation in castration-resistant prostate cancer: a case report. Mol Clin Oncol 2015;3:1392–4.doi:10.3892/mco.2015.645 pmid:http://www.ncbi.nlm.nih.gov/pubmed/26807253
  22. ↵
    1. Young J ,
    2. Haissaguerre M ,
    3. Viera-Pinto O , et al
    . Management of endocrine disease: Cushing's syndrome due to ectopic ACTH secretion: an expert operational opinion. Eur J Endocrinol 2020;182:R29–58.doi:10.1530/EJE-19-0877 pmid:http://www.ncbi.nlm.nih.gov/pubmed/31999619

Use of this content is subject to our disclaimer